Comparison of plasminogen activator inhibitor-1 concentration in Insulin-resistant versus insulin-sensitive healthy women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 11, 1999, Pages 2818-2821

  Abbasi, Fahim ^a   McLaughlin, Tracey ^a   Lamendola, Cindy ^a   Lipinska, Izabella ^b   Tofler, Geoffrey ^b,c   Reaven, Gerald M ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Shaman Pharmaceuticals Inc   (United States)

Author keywords

HDL cholesterol; Hyperinsulinemia; Insulin resistance; PAI 1; Triglycerides

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; OBESITY; PRIORITY JOURNAL;

EID: 0032719513     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.11.2818     Document Type: Article

References (19)

1. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor in angina pectoris: influence of plasma insulin and acute phase response. Arteriosclerosis. 1989;9:362-367.
2. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
3. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and athcrothrombosis. Diabetohgia. 1991;34:457-462.
4. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. Anerioscler Thromb. 1993;13: 1865-1873.
5. Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987;64:1169-1173.
6. Reaven GM, Brand RJ, Chen Y-DI, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes. 1993;42:1324-1332.
7. Nagi DK, Tracy R, Pratley R. Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. Metabolism. 1996;45:1243-1247.
8. Mykkanen L, Tapani R, Mamiemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
9. Toft I, Bfnaa KH, Ingebretsen, OC, Nordfy A, Birkeland KI, Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndronie in essential hypertension. Anerioscler Tliromb Vase Biol. 1997;17:553-559.
10. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Thromb Vasc Biol. 1998;18:258-264.
11. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Eng J Med. 1985;313:1557-1563.
12. Lijnen HR, Collen D. Impaired fibrinolysts and the risk for coronary heart disease. Circulation. 1996;94:2052-2054.
13. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;8:1039-1057.
14. Harano Y, Ohgaku S, Hidaka H, Haneda K, Kikkawa R, Shigeta Y, Abe H. Glucose insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Melab. 1977;45:1124-1127.
15. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulinmediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest. 1970;49:2151-2160.
16. Greenfield MS, Doberne L, Kraemer FB, Tobey TA, Reaven GM. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes. 1981;30:387-392.
17. Carantoni M, Abbasi F, Chu L, Chen Y-DI, Azhar S, Reaven GM. Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM. Diabetes Care. 1997;20:1462-1465.
18. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.
19. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen Y-DI, Sands RE, Pei D, Savage PJ, Bergman RM, for the Insulin Resistance Atherosclerosis Study. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes. 43:1114-1121.